Benitec Biopharma (BNTC) Capital Expenditures (2020 - 2025)

Benitec Biopharma (BNTC) reported Capital Expenditures of $18000.0 for Q1 2025, up 1700.0% sequentially from $1000.0 in Q2 2023.

Benitec Biopharma (BNTC) Capital Expenditures (2020 - 2025) Analysis & Trends

Benitec Biopharma (BNTC) has 5 years of Capital Expenditures data on file, last reported at $18000.0 in Q1 2025.

For the quarter ending Q1 2025, Capital Expenditures changed N/A year-over-year to $18000.0; the trailing twelve-month figure through Jun 2025 stood at $19000.0 (up 35.71% YoY), and the FY2025 full-year result was $18000.0, down 89.94% from the prior year.
Capital Expenditures improved to $18000.0 in Q1 2025, from $1000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $18000.0 in Q1 2025 to a low of -$141000.0 in Q2 2021.
A 4-year average of -$18800.0 and a median of $13000.0 in 2022 frame the typical range for Capital Expenditures.
Across the five-year window, Capital Expenditures sank 1184.62% in 2021 and jumped 109.22% in 2022, its largest moves.
Tracing BNTC's Capital Expenditures over 4 years: stood at -$141000.0 in 2021, then jumped by 109.22% to $13000.0 in 2022, then sank by 92.31% to $1000.0 in 2023, then soared by 1700.0% to $18000.0 in 2025.
Business Quant data shows BNTC's Capital Expenditures at $18000.0 in Q1 2025, $1000.0 in Q2 2023, and $13000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Benitec Biopharma	46.45 Mn	46.45 Mn	-	-

Download Data